Company intelligence / Profile preview
149 Bio
Miami, Florida, USAallositetx.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
149 Bio, operating as AlloSite Therapeutics, is a clinical-stage biotechnology company focused on developing allosteric agonists of integrin receptors to treat kidney and immune-mediated diseases. The company utilizes its proprietary CellStaple platform, an AI-driven discovery engine, to identify novel small molecules and antibodies that activate integrins rather than inhibiting them. Its lead candidate, ONT01 (formerly GB1275), is an oral CD11b activator currently in Phase 1/2 development for Lupus Nephritis. 149 Bio is also advancing a preclinical program targeting integrin alpha3beta1 for the treatment of focal segmental glomerulosclerosis (FSGS). The company was founded by Dr. Vineet Gupta, a leading expert in integrin biology and allosteric modulation.
- Therapeutic areas
- NephrologyImmunology
- Modalities
- Small moleculeMonoclonal antibodyAntibody
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Gossamer Bio
Beyond the preview
Go deeper on 149 Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 149 Bio.